PAP
SABS icon

Persistent Asset Partners’s SAB Biotherapeutics SABS Stock Holding History

Persistent Asset Partners’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$267K Buy
69,732
+49,942
+252% +$199K 0.1% 163
2025
Q4 		$74K Buy
+19,790
New +$65.1K 0.03% 280

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Persistent Asset Partners's SABS Position: Q1 2026 in Review

Persistent Asset Partners increased its SAB Biotherapeutics (SABS) stake by 252% in Q1 2026, buying an estimated $199K and bringing the position to 69,732 shares worth $267K. The position accounts for 0.1% of the portfolio, ranked #163.

Persistent Asset Partners first reported a position in SABS in Q4 2025 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Persistent Asset Partners held 69,732 shares of SAB Biotherapeutics worth $267K as of Q1 2026.
  • Persistent Asset Partners bought 49,942 SAB Biotherapeutics shares in Q1 2026, an estimated $199K.
  • SAB Biotherapeutics made up 0.1% of Persistent Asset Partners's portfolio in Q1 2026, its #163 holding.
  • Persistent Asset Partners first reported a position in SAB Biotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.